Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
AbbVie $4 billion senior notes offering
The investment-grade notes are due 2028, 2030, 2035 and 2055
Pacific Gas and Electric $1.75 billion first-mortgage bonds offering
The investment-grade bonds are due 2035 and 2055
Altisource exchange and maturity extension
We advised an ad hoc group of term loan lenders on the transaction
Rollins $500 million debut senior notes offering
The investment-grade notes are due 2035
Cisco Systems $5 billion notes offering
The investment-grade offering comprises five tranches of notes
Strategy $2 billion convertible notes offering
The convertible notes are due 2030
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
Incora emerges from chapter 11
We advised an ad hoc group of secured noteholders in connection with Incora’s chapter 11 proceedings
Eastman Chemical $250 million notes offering
The investment-grade notes are due 2029
Solid Biosciences $200 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market